Juno Therapeut…
ProfileJobs

Juno Therapeutics

Suggest Edit
    • Healthbiotechclinicspharmaplatform
    Juno Therapeutics develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. The Company is exploring the potential of its CAR and TCR technologies against targets that have the potential to treat cancers beyond B cell malignancies and multiple myeloma, in particular, difficult-to-treat solid organ tumors, such as certain breast, lung and pancreatic cancers.
    Revenue(FY, 2016)
    $79.4 M
    Market capitalization(2018-02-26)
    $9.1 B
    Patent Applications (FY, 2016)
    481
    Type
    Public
    Parent Company
    Celgene Corporation
    HQ
    Seattle, US
    Founded
    2013
    Size (employees)
    589 (est)
    Website
    junotherapeutics.com
    Juno Therapeutics was founded in 2013 and is headquartered in Seattle, US
    Report incorrect company information

    Key People/Management at Juno Therapeutics

    Hans Bishop

    Hans Bishop

    CEO
    Hyam Levitsky

    Hyam Levitsky

    EVP, Chief Scientific Officer
    Steve Harr

    Steve Harr

    CFO & Head of Corporate Development
    Bob Azelby

    Bob Azelby

    EVP, Chief Commercial Officer
    Cindy Elkins

    Cindy Elkins

    Chief Information Officer
    Mark Gilbert

    Mark Gilbert

    SVP, Chief Medical Officer
    Show more

    Juno Therapeutics Office Locations

    Juno Therapeutics has offices in München, Göttingen, Waltham, Bothell and in 2 other locations
    Seattle, US (HQ)
    300 307 Westlake Ave N
    Bothell, US
    18333 120th Ave NE
    Brisbane, US
    2000 Sierra Point Pkwy
    Waltham, US
    950 Winter St
    Göttingen, DE
    28 Rudolf-Wissell-Straße
    München, DE
    10 Grillparzerstraße
    Show all (6)
    Report incorrect company information

    Juno Therapeutics Financials and Metrics

    Juno Therapeutics Financials

    Juno Therapeutics's revenue was reported to be $79.36 m in FY, 2016 which is a 335.7% increase from the previous period.
    USD

    Revenue (Q3, 2017)

    		44.8 m

    Net income (Q3, 2017)

    		(118.1 m)

    EBIT (Q3, 2017)

    		(121.8 m)

    Market capitalization (26-Feb-2018)

    		9.1 b

    Cash (30-Sep-2017)

    		449.8 m
    Juno Therapeutics's current market capitalization is $9.1 b.
    Annual
    USDFY, 2015FY, 2016

    Revenue

    		18.2 m79.4 m

    Revenue growth, %

    		336%

    General and administrative expense

    		4.2 m70.7 m

    R&D expense

    		46.2 m264.3 m
    Quarterly
    USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

    Revenue

    		12.5 m1.6 m9.8 m27.6 m20.8 m19.3 m21.3 m44.8 m

    General and administrative expense

    		6.7 m14.9 m13.6 m16 m16.8 m18.4 m20.7 m23.6 m26.3 m

    R&D expense

    		57.8 m60.2 m11.5 m73.7 m72.3 m60.9 m82.9 m101.1 m140.3 m

    Operating expense total

    		65.2 m80.4 m25.1 m89.7 m89.1 m79.3 m103.7 m124.7 m166.6 m
    show all
    Annual
    USDFY, 2015FY, 2016

    Cash

    		252.4 m187.9 m

    Accounts Receivable

    		315 k13.3 m

    Inventories

    		8.4 m26.5 m

    Current Assets

    		951.8 m772.3 m
    Quarterly
    USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

    Cash

    		164.2 m39.5 m569.1 m316 m285.3 m223.4 m205.7 m218.7 m449.8 m

    Accounts Receivable

    		9.3 m10.6 m8.8 m10.4 m34.3 m

    Current Assets

    		400.7 m307.8 m1.2 b956 m974.6 m844.8 m779.5 m736.6 m972.5 m

    PP&E

    		15.4 m28.7 m36.9 m45 m51.5 m57.7 m102.5 m124.3 m131.6 m
    show all
    Annual
    USDFY, 2015FY, 2016

    Net Income

    		(51.8 m)(245.6 m)

    Depreciation and Amortization

    		2 k14.2 m

    Accounts Payable

    		(2.7 m)3.7 m

    Cash From Operating Activities

    		(103.6 m)(189.8 m)
    Quarterly
    USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

    Net Income

    		(65 m)(66 m)(23.2 m)(71.1 m)(64.8 m)(56.9 m)(82.2 m)

    Depreciation and Amortization

    		1 m

    Accounts Payable

    		(27 k)1.9 m3 m2.2 m3.2 m3.7 m3.2 m

    Cash From Operating Activities

    		(21.6 m)
    show all
    USDY, 2017

    Revenue/Employee

    		76.1 k

    Financial Leverage

    		1.3 x
    Show all financial metrics

    Juno Therapeutics Operating Metrics

    Juno Therapeutics's Patent Applications was reported to be 481 in FY, 2016.
    FY, 2016

    Patent Applications

    		481

    Patents (US)

    		72

    Patents (foreign)

    		86
    Show all operating metrics
    Report incorrect company information

    Competitors

    Kite Pharma
    Health - Subsidiary
    Mitra Biotech
    Health - Private
    KemPharm
    Health - Public
    WaferGen Biosystems
    Health - Subsidiary
    Compare competitors

    Juno Therapeutics News and Updates

    January 22, 2018

    Juno Therapeutics CEO Bishop set for $200M+ payday with Celgene buyout

    Juno Therapeutics CEO Hans Bishop is in line for a nice payday when his company seals the deal with Celgene. Think $200 million or more.
    Report incorrect company information
    Download PDF